Lonsurf® (FTD/TPI, Taiho Oncology) is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Read efficacy and safety information.
The 2026 NCCN Fall Policy Summit explored the current state of cancer screening and prevention services in the US, barriers that still drive disparities in screening uptake, and strategies to shift the paradigm of preventive cancer care.
